Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M08D1 in Combination With Immunochemotherapy in Diffuse Large B-Cell Lymphoma
NCT07818499Phase 2Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M08D1 in diffuse large B-cell lymphoma (DLBCL), sponsored by Biokin Pharmaceutical. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BL-M08D1
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07818499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818499.